Mount Sinai investigators used machine learning tools and a proteogenomic strategy to identify a 64-protein signature that predicted which tumors didn’t respond to first-line platinum-based therapy. This study analyzed 242 HGSOC tumor samples from patients who responded and did not respond to chemotherapy.
“The work also implicates possible therapeutic targets for these patients,” according to an Aug. 3 Mount Sinai news release.
More than 185,000 patients die from epithelial ovarian cancer each year; 60 percent of these deaths are caused by HGSOC. The mortality rate for this disease has not improved in the past four decades.
“Currently, there’s no way to distinguish refractory cases, leading some patients to unnecessarily experience the adverse effects of platinum-based chemotherapy without the benefits,” the news release said.
Becker’s 3rd Annual Fall Chief Pharmacy Officer Summit is the top tier event that the people leading the future of pharmacy convene. This 3-day event is built specifically for Chief Pharmacy Officers and senior pharmacy leaders. The sessions examine the workforce, financial and clinical priorities shaping pharmacy today. Becker’s is where candid discussions flourish and new ideas thrive. Becker's 3rd Annual Fall Chief Pharmacy Officer Summit
